Because of its high death rate and lack of effective treatments, cancer remains one of the most deadly chronic illnesses to this day. Traditional cancer treatments, such as radiotherapy, chemotherapy, or surgery, have few anti-tumor effects and can cause serious side effects. During the research on cancer therapies, anti-immune checkpoint antibody is emerging as promising targets as they stimulate natural immune responses. To promote this research, Creative Biolabs is proposing a variety of Next-IOTM program and a chance to co-develop these programs. This program aims to develop the therapeutic monoclonal antibody against LILRB1, specifically.
Learn more: Next-IO™ Anti-LILRB1 Monoclonal Antibody Program
